# Natera

Signatera holds EU IVDR certification across multiple cancers, FDA companion-diagnostic approval in muscle-invasive bladder cancer, an NCCN-guideline recommendation for bladder-cancer ctDNA-MRD testing, and a broad clinical launch of the ultra-sensitive Signatera Genome MRD test.

Source: https://en.bioecon.ru/companies/natera/
Updated: 2026-07-20

- Country: United States
- Ticker: NTRA

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Certification | Signatera holds EU IVDR Class C certification across multiple cancers | https://investor.natera.com/news/news-details/2026/Natera-Announces-IVDR-Certification-for-Signatera-Across-Multiple-Cancers/default.aspx, https://www.natera.com/company/news/natera-announces-ivdr-certification-for-signatera-across-multiple-cancers/ |
| Regulatory approval | FDA companion-diagnostic approval for Signatera in muscle-invasive bladder cancer | https://investor.natera.com/news/news-details/2026/Natera-Announces-IVDR-Certification-for-Signatera-Across-Multiple-Cancers/default.aspx, https://investor.natera.com/news/news-details/2026/Signatera-CDx-Approved-by-the-FDA-as-a-Companion-Diagnostic-in-Muscle-Invasive-Bladder-Cancer-MIBC/default.aspx, https://www.natera.com/company/news/natera-reports-second-quarter-2026-financial-results/, https://www.natera.com/company/news/nccn-recommends-ctdna-mrd-testing-using-signatera-technology-in-landmark-bladder-cancer-guideline-update/ |
| Regulatory approval | PMDA approval in Japan for colorectal cancer | https://investor.natera.com/news/news-details/2026/Natera-Announces-IVDR-Certification-for-Signatera-Across-Multiple-Cancers/default.aspx, https://www.natera.com/company/news/natera-announces-ivdr-certification-for-signatera-across-multiple-cancers/ |
| Production site | Laboratories in Austin, Texas; San Carlos, California; and Boulder, Colorado (subsidiary) | https://www.natera.com/company/news/natera-announces-expansion-in-austin-creating-what-is-believed-to-be-the-largest-sequencing-facility-in-the-world/ |
| Capacity | Expansion in Austin designed to have the largest sequencing capacity in the world | https://www.natera.com/company/news/natera-announces-expansion-in-austin-creating-what-is-believed-to-be-the-largest-sequencing-facility-in-the-world/ |
| Revenue | $2,306.1 million in 2025 | https://www.sec.gov/Archives/edgar/data/1604821/000110465926020881/ntra-20251231x10k.htm |
| Revenue | 2026 revenue guidance of $2.74 billion to $2.82 billion | https://investor.natera.com/news/news-details/2026/Natera-Reports-First-Quarter-2026-Financial-Results/default.aspx |
| Headcount | Expects to create up to 400 new jobs through Austin expansion | https://investor.natera.com/news/news-details/2026/Natera-Reports-First-Quarter-2026-Financial-Results/default.aspx, https://www.natera.com/company/news/natera-announces-expansion-in-austin-creating-what-is-believed-to-be-the-largest-sequencing-facility-in-the-world/, https://www.natera.com/company/news/natera-reports-second-quarter-2026-financial-results/ |

Independent sources: sec.gov

## Technologies

- [Liquid biopsy & ctDNA diagnostics](https://en.bioecon.ru/technology/liquid-biopsy-ctdna-diagnostics/)